Sep 2026
Abstract IA003: Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy
Pancreatic ductal adenocarcinoma (PDAC) is predicted to emerge as the second leading cause of cancer related death by 2030. Many treatment options that are successful in other cancer types, including immune checkpoint blockade, are generally ineffective in PDAC and the 5-year survival rate has remained stagnant for d...
Alex M. Jaeger, Emma Adhikary, Andrew Deonarine et al.
· Cancer Research · 0 citations